Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10601439	
Filing Date		2003-06-23	
First Named Inventor	Dz-cl	hing Ju	
Art Unit		2192	
Examiner Name	Not Y	Yet Assigned	
Attorney Docket Numb	er	20002/16406	

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Issue Date Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wisl	h to a	i dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	Name of Patentee or Applicant of cited Document			Relev	s,Columns,L ant Passag es Appear		
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d butto			
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Cite Foreign Document Country Code ² i Code ⁴		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colu where Rele Passages of Figures Ap	vant or Relevant	+4				
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add							_				
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Cite Initiats* Cite Initiats* No Universe in Color (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Тs					

	Application Number		10601439
INFORMATION DIGGS COURT	Filing Date		2003-06-23
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Dz-ching Ju		hing Ju
(Not for submission under 37 CFR 1.99)	Art Unit		2192
	Examiner Name Not Y		et Assigned
	Attorney Docket Number		20002/16406

	1	Intel® Itanium® Architecture Software Developer's Manual, Volume 3: Instruction Set Reference, Revision 2.1, October 2002, Document No. 245319-004, 558 pages.	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible, *Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10601439	
Filing Date		2003-06-23	
First Named Inventor	Dz-ching Ju		
Art Unit		2192	
Examiner Name	Not Y	et Assigned	
Attorney Docket Numb	er	20002/16406	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appropriate selection(s):
---------------	----------	-------------	------------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 137(a)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 178(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 178(v2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael W. Zimmerman/	Date (YYYY-MM-DD)	2006-10-05
Name/Print	Michael W. Zimmerman	Registration Number	57993

This collection of information is required by 3 T CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3 T CPR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Operatment of Comments. P. D. 68. 1430, Alexandria, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.